News Quantified

LGND – ligand pharmaceuticals incorporated (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Ligand Pharmaceuticals (NASDAQ:LGND) had its "hold (c)" rating reaffirmed by analysts at Weiss Ratings.

How Ligand Pharmaceuticals' Strong Q3 Results and Raised Guidance May Impact LGND Investors [Yahoo! Finance]

What Makes Ligand Pharmaceuticals (LGND) an Investment Choice? [Yahoo! Finance]

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year [Yahoo! Finance]

Ligand Pharmaceuticals (NASDAQ:LGND) had its "hold (c-)" rating reaffirmed by analysts at Weiss Ratings.

4.6%

BEAT

1.9%

BEAT

-2.5%

BEAT

1.4%

BEAT

Form 4 LIGAND PHARMACEUTICALS For: Dec 01 Filed by: KOZARICH JOHN W

Form 144 LIGAND PHARMACEUTICALS Filed by: KOZARICH JOHN W

Form SCHEDULE 13G/A LIGAND PHARMACEUTICALS Filed by: JANUS HENDERSON GROUP PLC

Form 4 LIGAND PHARMACEUTICALS For: Nov 07 Filed by: Gray Nancy Ryan

Form 4 LIGAND PHARMACEUTICALS For: Nov 07 Filed by: LAMATTINA JOHN L

Top News Gainers

3/17 Ligand Pharmaceuticals Inc. (NASDAQ: LGND) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 24.8%

11/8 Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol 7.1%

3/2 Ligand Pharmaceuticals Management to Present at Two Investor Conferences in March 6.5%

9/12 Form 8-K LIGAND PHARMACEUTICALS For: Aug 27 6.3%

4/8 Ligand Pharmaceuticals Inc. (NASDAQ: LGND) had its price target lowered by analysts at HC Wainwright from $237.00 to $229.00. 6.2%

4/6 Ligand Provides a Corporate Update and Announces May 6th as the Date for First Quarter Earnings Call 5.7%

9/19 Ligand Pharmaceuticals Inc. (NASDAQ: LGND) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating. They now have a $132.00 price target on the stock, up previously from $110.00. 5.5%

3/24 Ligand Pharmaceuticals Inc. (NASDAQ: LGND) was downgraded by analysts at Argus from a "buy" rating to a "hold" rating. 5.2%

6/3 Form 8-K LIGAND PHARMACEUTICALS For: May 31 4.3%

7/31 Form 4 LIGAND PHARMACEUTICALS For: Jul 31 Filed by: HIGGINS JOHN L 4.2%

Top News Decliners

3/13 Form 4 LIGAND PHARMACEUTICALS For: Mar 13 Filed by: FOEHR MATTHEW W -21.8%

7/30 Q2/2019 6/30/2019 EPS 0.680 ZacksConsensus 0.380 ActVsEst 0.300 - Beat -12.6%

2/27 Form 4 LIGAND PHARMACEUTICALS For: Feb 27 Filed by: FOEHR MATTHEW W -9.5%

11/6 Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] -8.6%

3/27 Ligand Pharmaceuticals Inc. (NASDAQ: LGND) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -7.2%

8/5 Ligand Pharmaceuticals Inc. (NASDAQ: LGND) had its price target lowered by analysts at Barclays PLC from $131.00 to $110.00. They now have an "equal weight" rating on the stock. -6.8%

3/10 Ligand Pharmaceuticals (LGND) Presents At Barclays Global Healthcare Conference - Slideshow [Seeking Alpha] -6.4%

6/10 Form 8-K LIGAND PHARMACEUTICALS For: Jun 06 -4.7%

11/13 Form 4 LIGAND PHARMACEUTICALS For: Nov 12 Filed by: FOEHR MATTHEW W -4.7%

3/17 Ligand Pharmaceuticals (LGND) Presents At 32nd Annual ROTH Conference - Slideshow [Seeking Alpha] -4.7%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day